SALE: For a limited time only we are offering Patent Investor+ for $249/mo. Learn More
Nov 14, 2017
1 min read
AMP trims position in NKTR
Yesterday AMP trimmed its position in Nektar Therapeutics by trimming 33% of its position. Buoyed by recent positive Ph1/2 results for NKTR-214 in solid tumors in combination with Opdivo, AMP's position was up ~200% at the time of the sale.